DESTINY-Breast03 Phase 3 Study Results

Secondary Endpoints 0.75 0.5 0.25 0 T 5 10 15 Time Numbers at risk 14 11 0 ■ 5 7 1 10 15 PFS: 14 months (95% CI 11.0-n.r.) - Median follow-up 11 months (range 3 – 17 months) ESMO BC 2022 #165 Mini Oral Daiichi-Sankyo ◉ ☐ Clinical Benefit Rate (CR+PR+SD ≥6 months): 13/15 (86.7%) in the ITT population and 13/14 (92.9%) in the PP population Median OS not reached Extracranial Response Rate: Pts. with extracranial metastases at baseline (n=13): PR 5/13 (27.8%) Pts with measurable extracranial disease at baseline (n=8): PR 5/8 (62.5%) 56

View entire presentation